Expert Opinion on Orphan Drugs

609 papers and 3.4k indexed citations i.

About

The 609 papers published in Expert Opinion on Orphan Drugs in the last decades have received a total of 3.4k indexed citations. Papers published in Expert Opinion on Orphan Drugs usually cover Molecular Biology (203 papers), Pulmonary and Respiratory Medicine (113 papers) and Genetics (91 papers) specifically the topics of Lysosomal Storage Disorders Research (44 papers), Health Systems, Economic Evaluations, Quality of Life (38 papers) and Genomics and Rare Diseases (33 papers). The most active scholars publishing in Expert Opinion on Orphan Drugs are Tadao Orii, Shunji Tomatsu, Robert E. MacLaren, Manuel Posada de la Paz and Robert W. Mason.

In The Last Decade

Fields of papers published in Expert Opinion on Orphan Drugs

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Expert Opinion on Orphan Drugs. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Expert Opinion on Orphan Drugs

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Expert Opinion on Orphan Drugs. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Expert Opinion on Orphan Drugs with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025